Navigation Links
Vanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
Date:12/3/2013

WASHINGTON, Dec. 3, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will deliver a corporate presentation at the 25th Annual Piper Jaffray Healthcare Conference in New York City on Wednesday, December 4, 2013 at 11:30 a.m. Eastern Time.

The presentation at the Piper Jaffray Healthcare Conference will be available live on Vanda's corporate website, where it also will be archived for 30 days.  To access the presentation, go to Vanda's website at www.vandapharma.com and click on the Presentations tab on the Investor Relations page.  Please connect to the website several minutes prior to the start of the live presentation.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

Investor Contact:
Chad Rubin
Vice President
The Trout Group
(646) 378-2947
crubin@troutgroup.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
2. Nieuwe behandeloptie vandaag geïntroduceerd voor artsen die patiënten behandelen met veelvuldig recidiverend of refractair agressief B-cel-non-hodgkinlymfoom
3. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
4. Vanda Pharmaceuticals Reports First Quarter 2013 Results
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
8. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
9. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
10. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
11. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer and recently formed ... entered into a multiyear collaboration to identify and characterize novel CRISPR-Cas nucleases. The ... gene editing across all applications. , Under the terms of the agreement, Pioneer ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract research, ... improve patient outcomes and quality of life, will now be offering its impurity ... to new regulatory requirements for all new drug products, including the finalization of ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... Md. (PRWEB) , ... October 11, 2017 , ... ... digital pathology, announced today it will be hosting a Webinar titled, “Pathology is ... Advanced Pathology Associates , on digital pathology adoption best practices and how Proscia ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... prestigious international IAIR Award for the most innovative high security ePassport and ... ... Maldives Immigration Controller General, Mr. Mohamed ... the right) have received the IAIR award for the "Most innovative high ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by ... Global Forecast to 2022", published by MarketsandMarkets, the market is expected to be ... 2017 and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):